Clinical Trials
As one of the best drug development programs in the country, our clinical pharmacologists conduct more clinical trials than any pediatric cancer center in the nation and are leaders in the development of new chemotherapy treatments for pediatric cancer.
More than 260 treatment studies
Texas Children's Cancer and Hematology Centers have more than 260 clinical trials underway to determine the safety and effectiveness of drug treatments in children. Approximately, 80% of our patients are involved in clinical trials. Our Drug Development and Pharmacology Program has developed a number of new anti-cancer agents currently undergoing clinical trials within Texas Children's Cancer and Hematology Centers, which means our patients have access to the newest and most advanced therapies.
Every patient is considered for leading-edge therapies
Recognizing that clinical trials are the standard of care for all children with cancer, every eligible patient is considered for entry in National Cancer Institute-approved trials, and the vast majority are registered in these studies. These treatment protocols represent leading-edge therapies in the field, to provide the best treatments for children with cancer.
Stay Up-to-Date: Subscribe to our e-Newsletter
Our Clinical Trials e-Newsletter is designed to provide you with information regarding the latest clinical trials available at Texas Children's Cancer and Hematology Centers.
Featured Clinical Trials
- ADVL1014: A Phase I Dose Escalation Study of Reolysin, a Replication Competent Reovirus, in Pediatric Patients with Relapsed or Refractory Solid Tumors
Relapsed or refractory solid tumors with the exception of central nervous system tumors and lymphomas
- Read More
- ADVL0911: A Phase I Study of Seneca Valley Virus (NTX-010)
Neuroblastoma, rhabdomyosarcoma, Wilms’ tumor, retinoblastoma, adrenocortical carcinoma or carcinoid tumor
- Read More
- A Phase 1 Dose Esclation Study Of Jx-594, An Attenuated Oncolytic Virus, Administered By Intratumoral Injection In Pediatric Patients With Unresectable Refractory Solid Tumors (Jx594-It-P009)
Relapsed or refractory solid tumors with the exception of brain tumors, other central nervous system tumors, and lymphomas.
- Read More
- ADVL1114: A Phase 1 Study of Temsirolimus in Combination with Intensive Re-Induction Therapy for Children with Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkin Lymphoma
Patients must have 2nd or greater relapse of pre-B ALL, T-cell ALL, lymphoblastic l ymphoma, or peripheral T-cell lymphoma.
- Read More
- PBTC-033: A Phase I/II Study of ABT-888, an Oral Poly (ADP-ribose) Polymerase Inhibitor, and Concurrent Radiation Therapy, followed by ABT-888 and Temozolomide, in Children with Newly Diagnosed Diffuse Pontine Gliomas
Newly diagnosed pediatric brain tumor patients with a diffuse pontine glioma
- Read More